Cathelicidin suppresses lipid accumulation and hepatic steatosis by inhibition of the CD36 receptor.

ABSTRACT:

Background and objectives

Obesity is a global epidemic which increases the risk of the metabolic syndrome. Cathelicidin (LL-37 and mCRAMP) is an antimicrobial peptide with an unknown role in obesity. We hypothesize that cathelicidin expression correlates with obesity and modulates fat mass and hepatic steatosis.

Materials and methods

Male C57BL/6 J mice were fed a high-fat diet. Streptozotocin was injected into mice to induce diabetes. Experimental groups were injected with cathelicidin and CD36 overexpressing lentiviruses. Human mesenteric fat adipocytes, mouse 3T3-L1 differentiated adipocytes and human HepG2 hepatocytes were used in the in vitro experiments. Cathelicidin levels in non-diabetic, prediabetic and type II diabetic patients were measured by enzyme-linked immuno

SUBMITTER: Hoang-Yen Tran D 

PROVIDER: S-EPMC5014693 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature